The aim of this study was to determine the interaction between cerebral amyloid angiopathy (CAA) and Braak staging on cognition in the elderly. The study used a total of 141 subjects consisting of 72 non-cognitively impaired (NCI), 33 mild cognitive impairment (MCI), 36 Alzheimer’s disease (AD) cases displaying Braak stages 0-II and III from the Rush Religious Order Study cohort. The association between Braak stage and CAA status and cognition was evaluated using a series of regression models that adjusted for age at death, sex, education, APOEɛ4 status, and Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropathological diagnosis. Individuals with CAA were more likely to be classified as Braak stage III relative to those without CAA [OR = 2.33, 95% CI (1.06, 5.14), p = 0.04]. A significant interaction was found between Braak stage and CAA status on a global cognitive score (β = –0.58, SE = 0.25, p = 0.02). Episodic memory also showed a significant association between Braak stage and CAA (β= –0.75, SE = 0.35, p = 0.03). These data suggest that there is a significant interaction between tau pathology and cerebrovascular lesions on cognition within the AD clinical spectrum.
QianJ, HymanBT, BetenskyRA (2017) Neurofibrillary tangle stage and the rate of progression of Alzheimer symptoms: Modeling using an autopsy cohort and application to clinical trial design. JAMA Neurol74, 540–548.
5.
AbnerEL, KryscioRJ, SchmittFA, SantacruzKS, JichaGA, LinY, NeltnerJM, SmithCD, Van EldikLJ, NelsonPT (2011) “End-stage” neurofibrillary tangle pathology in preclinical Alzheimer’s disease: Fact or fiction?J Alzheimers Dis25, 445–453.
6.
RileyKP, SnowdonDA, MarkesberyWR (2002) Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study. Ann Neurol51, 567–577.
LangbaumJBS, FleisherAS, ChenK, AyutyanontN, LoperaF, QuirozYT, CaselliRJ, TariotPN, ReimanEM (2013) Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol9, 371–381.
9.
MufsonEJ, Malek-AhmadiM, PerezSE, ChenK (2016) Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiol Aging37, 147–153.
10.
MufsonEJ, Malek-AhmadiM, PerezSE, SnyderN, AusdemoreJ, ChenK, PerezSE (2016) Braak stage and trajectory of cognitive decline in non-cognitively impaired elders. Neurobiol Aging43, 101–110.
11.
MartinsIJ, HoneE, FosterJK, Sünram-LeaSI, GnjecA, FullerSJ, NolanD, GandySE, MartinsRN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry11, 721–736.
12.
KulstadJJ, GreenPS, CookDG, WatsonGS, RegerMA, BakerLD, PlymateSR, AsthanaS, RhoadsK, MehtaPD, CraftS (2006) Differential modulation of plasma beta amyloid by insulin in patients with Alzheimer disease. Neurology66, 1506–1510.
13.
MufsonEJ, IkonomovicMD, CountsSE, PerezSE, Malek-AhmadiM, ScheffSW, GinsbergSD (2016) Molecular and cellular pathophysiology of preclinical Alzheimer’s disease. Behav Brain Res311, 54–69.
14.
Kumar-SingS (2008) Cerebral amyloid angiopathy: Pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav7(Suppl 1), 67–82.
15.
BrenowitzWD, NelsonPT, BesserLM, HellerKB, KukullWA (2015) Cerebral amyloid angiopathy and its co-occurrence with Alzheimer’s disease and other cerebrovascular neuropathologic changes. Neurobiol Aging36, 2702–2708.
16.
BoylePA, YuL, NagS, LeurgansS, WilsonRS, BennettDA, SchneiderJA (2015) Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology85, 1930–1936.
17.
VidoniED, YehH-W, MorrisJK, NewellKL, AlqahtaniA, BurnsNC, BurnsJM, BillingerSA (2016) Cerebral amyloid angiopathy is associated with earlier dementia onset in Alzheimer’s disease. Neurodegener Dis16, 218–224.
18.
BosI, VerheyFR, RamakersIHGB, JacobsHIL, SoininenH, Freund-LeviY, HampelH, TsolakiM, WallinÅK, van BuchemMA, OleksikA, VerbeekMM, Olde RikkertM, van der FlierWM, ScheltensP, AaltenP, VisserPJ, VosSJB (2017) Cerebrovascular and amyloid pathology in predementia stages: The relationship with neurodegeneration and cognitive decline. Alzheimers Res Ther9, 101.
19.
IadecolaC (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol120, 287–296.
20.
Di MarcoLY, VenneriA, FarkasE, EvansPC, MarzoA, FrangiAF (2015) Vascular dysfunction in the pathogenesis of Alzheimer’s disease - A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis82, 593–606.
21.
Iturria-MedinaY, SoteroRC, ToussaintPJ, Mateos-PérezJM, EvansAC; Alzheimer’s Disease Neuroimaging Initiative (2016) Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun7, 11934.
22.
WenY, YangS-H, LiuR, Brun-ZinkernagelAM, KoulenP, SimpkinsJW (2007) Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta1772, 473–483.
23.
Basurto-IslasG, GuJH, TungYC, LiuF, IqbalK (2018) Mechanism of tau hyperphosphorylation involving lysosomal enzyme asparagine endopeptidase in a mouse model of brain ischemia. J Alzheimers Dis63, 821–833.
24.
MerliniM, WannerD, NitschRM (2016) Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer’s disease-related microvascular cerebral amyloid angiopathy. Acta Neuropathol131, 737–752.
25.
WilliamsS, ChalmersK, WilcockGK, LoveS (2005) Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer’s disease. Neuropathol Appl Neurobiol31, 414–421.
26.
WellerRO, HawkesCA, CarareRO, HardyJ (2015) Does the difference between PART and Alzheimer’s disease lie in the age-related changes in cerebral arteries that trigger the accumulation of Aβ and propagation of tau?Acta Neuropathol129, 763–766.
27.
KalariaRN (2000) The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging21, 321–330.
28.
KimHJ, ParkS, ChoH, JangYK, San LeeJ, JangH, KimY, KimKW, RyuYH, ChoiJY, MoonSH, WeinerMW, JagustWJ, RabinoviciGD, DeCarliC, LyooCH, NaDL, SeoSW (2018) Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging. JAMA Neurol75, 999–1007.
29.
BennettDA, SchneiderJA, ArvanitakisZ, WilsonRS (2012) Overview and findings from the Religious Order Study. Curr Alzheimer Res9, 628–645.
30.
MufsonEJ, ChenEY, CochranEJ, BeckettLA, BennettDA, KordowerJH (1999) Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol158, 469–490.
31.
BennettDA, WilsonRS, SchneiderJA, EvansDA, BeckettLA, AggarwalNT, BarnesLL, FoxJH, BachJ (2002) Natural history of mild cognitive impairment in older persons. Neurology59, 198–205.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
34.
Malek-AhmadiM, LuS, ChanY, PerezSE, ChenK, MufsonEJ (2017) Cognitive domain dispersion association with Alzheimer’s pathology. J Alzheimers Dis58, 575–583.
35.
BennettDA, SchneiderJA, BuchmanAS, Mendes de LeonC, BieniasJL, WilsonRS (2005) The Rush Memory and Aging Project: Study design and ine characteristics of the study cohort. Neuroepidemiology25, 163–175basel.
36.
BennettDA, SchneiderJA, WilsonRS (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol61, 378–184.
37.
SchneiderJA, AggarwalNT, BarnesL, BoyleP, BennettDA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis18, 691–701.
38.
MirraSS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: A commentary.. Neurobiol Aging18, S91–S94.
39.
The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging18, S1–S2.
40.
SchneiderJA, ArvanitakisZ, BangW, BennettDA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology69, 2197–2204.
41.
McKeithIG, GalaskoD, KosakaK, PerryEK, DicksonDW, HansenLA, SalmonDP, LoweJ, MirraSS, ByrneEJ, LennoxG, QuinnNP, EdwardsonJA, IncePG, BergeronC, BurnsA, MillerBL, LovestoneS, CollertonD, JansenEN, BallardC, de VosRA, WilcockGK, JellingerKA, PerryRH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology47, 1113–1124.
42.
JellingerKA (2009) A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. Biochim Biophys Acta1792, 730–740.
43.
MitchellTW, NissanovJ, HanLY, MufsonEJ, SchneiderJA, CochranEJ, BennettDA, LeeVM, TrojanowskiJQ, ArnoldSE (2000) Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem48, 1627–1638.
44.
LoveS, ChalmersK, InceP, EsiriM, AttemsJ, JellingerK, YamadaM, McCarronM, MinettT, MatthewsF, GreenbergS, MannD, KehoePG (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis3, 19–32. Erratum in: Am J Neurodegener Dis4, 49.
45.
BennettDA, SchneiderJA, ArvanitakisZ, KellyJF, AggarwalNT, ShahRC, WilsonRS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology66, 1837–1844.
46.
WilsonRS, LeurgansSE, BoylePA, BennettDA (2011) Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol68, 351–356.
47.
WennbergAM, WhitwellJL, TosakulwongN, WeigandSD, MurrayME, MachuldaMM, PetrucelliL, MielkeMM, JackCRJr, KnopmanDS, ParisiJE, PetersenRC, DicksonDW, JosephsKA (2019) The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiol Aging77, 26–36.
48.
DowlingNM, TomaszewskiFS, ReedBR, ReedBR, SonnenJA, StraussME, SchneiderJA, BennettDA, MungasD (2011) Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults. J Int Neuropsychol Soc17, 602–614.
49.
HeddenT, OhH, YoungerAP, PatelTA (2013) Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology80, 1341–1348.
50.
BancherC, JellingerK, LassmannH, FischerP, LeblhuberF (1996) Correlations between mental state and quantitative neuropathology in the Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci246, 137–146Vienna.
51.
NelsonPT, JichaGA, SchmittFA, LiuH, DavisDG, MendiondoMS, AbnerEL, MarkesberyWR (2007) Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol66, 1136–1146.
52.
Malek-AhmadiM, ChenK, PerezSE, HeA, MufsonEJ (2018) Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology. Alzheimers Res Ther10, 90.
53.
Malek-AhmadiM, PerezSE, ChenK, MufsonEJ (2016) Neuritic and diffuse plaque associations with memory in non-cognitively impaired elderly. J Alzheimers Dis53, 1641–1652.
54.
A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer’s disease (Generation S1). Accessed electronically on 12/20/18 at https://clinicaltrials.gov/ct2/show/NCT02565511
55.
A study of CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer’s disease (Generation S2). Accessed electronically on 12/20/18 at https://clinicaltrials.gov/ct2/show/NCT03131453
KarranE, De StrooperB (2016) The amyloid cascade hypothesis: Are we poised for success or failure?J Neurochem139 Suppl 2, 237–252.
59.
BoutajangoutA, WisniewskiT (2014) Tau-based therapeutic approaches for Alzheimer’s disease - a mini-review. Gerontology60, 381–385.
60.
YouY, PerkinsA, CisternasP, MuñozB, TaylorX, YouY, GarringerHJ, OblakAL, AtwoodBK, VidalR, Lasagna-ReevesCA (2019) Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy. Acta Neuropathol Commun7, 26.
61.
BrickmanAM, SiedleckiKL, MuraskinJ, ManlyJJ, LuchsingerJA, YeungLK, BrownTR, DeCarliC, SternY (2011) White matter hyperintensities and cognition: Testing the reserve hypothesis. Neurobiol Aging32, 1588–1598.
62.
RabinJS, YangHS, SchultzAP, HanseeuwBJ, HeddenT, ViswanathanA, GatchelJR, MarshallGA, KilpatrickE, KleinH, RaoV, BuckleyRF, YauWW, KirnDR, RentzDM, JohnsonKA, SperlingRA, ChhatwalJP (2019) Vascular risk and β-amyloid are synergistically associated with cortical tau. Ann Neurol85, 272–279.
63.
VemuriP, LesnickTG, PrzybelskiSA, KnopmanDS, LoweVJ, Graff-RadfordJ, RobertsRO, MielkeMM, MachuldaMM, PetersenRC, JackCRJr (2017) Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol82, 706–718.
64.
VemuriP, LesnickTG, PrzybelskiSA, KnopmanDS, PreboskeGM, KantarciK, RamanMR, MachuldaMM, MielkeMM, LoweVJ, SenjemML, GunterJL, RoccaWA, RobertsRO, PetersenRC, JackCRJr (2015) Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain138(Pt 3), 761–771.
65.
BrownWR, ThoreCR (2011) Review: Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol37, 56–74.
66.
MufsonEJ, BinderL, CountsSE, DeKoskyST, de Toledo-MorrellL, GinsbergSD, IkonomovicMD, PerezSE, ScheffSW (2012) Mild cognitive impairment: Pathology and mechanisms. Acta Neuropathol123, 13–30.
67.
BennettDA, WilsonRS, BoylePA, BuchmanAS, SchneiderJA (2012) Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol72, 599–609.
